388 related articles for article (PubMed ID: 21276828)
21. Serotonin 5-HT
García-Bea A; Miranda-Azpiazu P; Muguruza C; Marmolejo-Martinez-Artesero S; Diez-Alarcia R; Gabilondo AM; Callado LF; Morentin B; González-Maeso J; Meana JJ
Eur Neuropsychopharmacol; 2019 Dec; 29(12):1453-1463. PubMed ID: 31734018
[TBL] [Abstract][Full Text] [Related]
22. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
[TBL] [Abstract][Full Text] [Related]
23. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD
Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152
[TBL] [Abstract][Full Text] [Related]
24. Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.
Benneyworth MA; Smith RL; Sanders-Bush E
Neuropsychopharmacology; 2008 Aug; 33(9):2206-16. PubMed ID: 17957214
[TBL] [Abstract][Full Text] [Related]
25. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function.
Moreno JL; Muguruza C; Umali A; Mortillo S; Holloway T; Pilar-Cuéllar F; Mocci G; Seto J; Callado LF; Neve RL; Milligan G; Sealfon SC; López-Giménez JF; Meana JJ; Benson DL; González-Maeso J
J Biol Chem; 2012 Dec; 287(53):44301-19. PubMed ID: 23129762
[TBL] [Abstract][Full Text] [Related]
26. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
27. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
González-Maeso J; Weisstaub NV; Zhou M; Chan P; Ivic L; Ang R; Lira A; Bradley-Moore M; Ge Y; Zhou Q; Sealfon SC; Gingrich JA
Neuron; 2007 Feb; 53(3):439-52. PubMed ID: 17270739
[TBL] [Abstract][Full Text] [Related]
28. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.
Karaki S; Becamel C; Murat S; Mannoury la Cour C; Millan MJ; Prézeau L; Bockaert J; Marin P; Vandermoere F
Mol Cell Proteomics; 2014 May; 13(5):1273-85. PubMed ID: 24637012
[TBL] [Abstract][Full Text] [Related]
29. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
Buchborn T; Schröder H; Dieterich DC; Grecksch G; Höllt V
Behav Brain Res; 2015 Mar; 281():62-8. PubMed ID: 25513973
[TBL] [Abstract][Full Text] [Related]
30. Differences across sexes on head-twitch behavior and 5-HT
Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J
Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476
[TBL] [Abstract][Full Text] [Related]
31. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
[TBL] [Abstract][Full Text] [Related]
32. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
33. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.
Canal CE; Olaghere da Silva UB; Gresch PJ; Watt EE; Sanders-Bush E; Airey DC
Psychopharmacology (Berl); 2010 Apr; 209(2):163-74. PubMed ID: 20165943
[TBL] [Abstract][Full Text] [Related]
34. Metabotropic Glutamate
Benvenga MJ; Chaney SF; Baez M; Britton TC; Hornback WJ; Monn JA; Marek GJ
Front Pharmacol; 2018; 9():208. PubMed ID: 29599719
[TBL] [Abstract][Full Text] [Related]
35. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
Jalal B
Psychopharmacology (Berl); 2018 Nov; 235(11):3083-3091. PubMed ID: 30288594
[TBL] [Abstract][Full Text] [Related]
36. Psychedelics and schizophrenia.
González-Maeso J; Sealfon SC
Trends Neurosci; 2009 Apr; 32(4):225-32. PubMed ID: 19269047
[TBL] [Abstract][Full Text] [Related]
37. Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT
Contreras A; Khumnark M; Hines RM; Hines DJ
Sci Rep; 2021 Jan; 11(1):1925. PubMed ID: 33479368
[TBL] [Abstract][Full Text] [Related]
38. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.
Gewirtz JC; Marek GJ
Neuropsychopharmacology; 2000 Nov; 23(5):569-76. PubMed ID: 11027922
[TBL] [Abstract][Full Text] [Related]
39. Increased behavioral and neuronal responses to a hallucinogenic drug after adolescent toluene exposure in mice: Effects of antipsychotic treatment.
Lee MY; Lin BF; Chan MH; Chen HH
Toxicology; 2020 Dec; 445():152602. PubMed ID: 32980479
[TBL] [Abstract][Full Text] [Related]
40. Acute serotonin 2A receptor activation impairs behavioral flexibility in mice.
Amodeo DA; Hassan O; Klein L; Halberstadt AL; Powell SB
Behav Brain Res; 2020 Oct; 395():112861. PubMed ID: 32814148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
